All In Biotech

Drug Trial Radar · NCT00080301

Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer

A Phase III Trial of Novel Epothilone BMS-247550 Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Previously Treated With or Resistant to an Anthracycline and Who Are Taxane Resistant

Last checked: Nov 20, 2026Latest source record: Nov 2, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 752 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

752

Actual

Start

Sep 2003

Primary completion

Nov 2006

Study completion Mar 2008

Sponsor

Lead sponsor
R-PharmIndustry
Sponsor type
Industry
First posted
Mar 30, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical research study is to learn if BMS-247550 added to the approved therapy of capecitabine is better than capecitabine alone in shrinking or slowing the growth of the cancer in women with metastatic breast cancer who are resistant to taxane and received anthracycline chemotherapy. The safety of this treatment will also be studied.

Conditions

  • Breast Cancer
  • Metastases

Interventions

  • Ixabepilone + CapecitabineDrug

    Ixabepilone - Intravenous Solution, IV 40mg/m², Day 1 every 21 days, Until progression/unacceptable toxicity Capecitabine (Active Comparator) - Tablet, Oral, 2000 mg/m², Bid Days 1-14 every 21 days, Until progression/unacceptable toxicity

  • CapecitabineDrug

    Tablet, Oral, 2500 mg/m², Bid Days 1-14 every 21 days, Until progression/unacceptable toxicity

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS) Per Independent Radiology Review Committee (IRRC)Time frame: based on assessments every 6 weeks while on treatment until documented disease progression/unacceptable toxicity

Locations

127 sites in 22 countries. Site status is shown where the registry gives one.

  • Local Institution

    Little Rock, Arkansas

  • Local Institution

    San Francisco, California

  • Local Institution

    Vallejo, California

  • Local Institution

    Denver, Colorado

  • Local Institution

    Hartford, Connecticut

  • Local Institution

    Washington D.C., District of Columbia

  • Local Institution

    Orlando, Florida

  • Local Institution

    Baltimore, Maryland

  • Local Institution

    Burlington, Massachusetts

  • Local Institution

    Jackson, Mississippi

  • Local Institution

    Columbia, Missouri

  • Local Institution

    Kansas City, Missouri

  • Local Institution

    St Louis, Missouri

  • Local Institution

    Omaha, Nebraska

  • Local Institution

    Livingston, New Jersey

  • Local Institution

    New Brunswick, New Jersey

  • Local Institution

    Albuquerque, New Mexico

  • Local Institution

    New York, New York

  • Local Institution

    Columbus, Ohio

  • Local Institution

    Oklahoma City, Oklahoma

  • Local Institution

    Tulsa, Oklahoma

  • Local Institution

    Pittsburgh, Pennsylvania

  • Local Institution

    Columbia, South Carolina

  • Local Institution

    Greenville, South Carolina

  • Local Institution

    Knoxville, Tennessee

  • Local Institution

    Nashville, Tennessee

  • Local Institution

    Austin, Texas

  • Local Institution

    Houston, Texas

  • Local Institution

    Ogden, Utah

  • Local Institution

    Burlington, Vermont

  • Local Institution

    Tacoma, Washington

  • Local Institution

    Morgantown, West Virginia

  • Local Institution

    Córdoba, Argentina

  • Local Institution

    Neuquén, Argentina

  • Local Institution

    Santa Fe, Argentina

  • Local Institution

    Capital Federal, Buenos Aires, Argentina

  • Local Institution

    Haedo, Buenos Aires, Argentina

  • Local Institution

    La Plata, Buenos Aires, Argentina

  • Local Institution

    Mar del Plata, Buenos Aires, Argentina

  • Local Institution

    Pilar, Buenos Aires, Argentina

Showing 40 of 127 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.